Ensuring patient safety is one of the biggest concerns in the pharmaceutical industry. Preclinical safety testing can occur at multiple points during the drug development process, and taken together can inform on the risks of certain therapies to human health and provide valuable information on safe dosing strategies. The role of the immunotoxicologist is to assess the impact of drugs on the immune system, both unintended toxic effects and in cases of intended, exaggerated pharmacology. There are many tools that immunotoxicologists use to assess immune responses following drug treatment in preclinical animal models. While current guidances have basic recommendations for testing strategies, each program and target are handled on a case-by-case basis. This strategy will be demonstrated in two case studies of a biological-derived and small molecule therapeutic.

Tuesday, November 6, 2018
4:15 p.m. in Stowell Hall Room 211, SUNY Potsdam
Light refreshments will be served. All are welcome.